Category Archives: Press Release

PharmaMar presents new data on Yondelis® (trabectedin) in combination with immunotherapy at ESMO

PharmaMar has presented new results for ZepzelcaTM (lurbinectedin) in sensitive patients with Small-Cell Lung Cancer, candidates for “re-challenge”

PharmaMar will present data for ZepzelcaTM (lurbinectedin) and Yondelis® (trabectedin) at ESMO 2020

PharmaMar crea una nueva Unidad de Virología

PharmaMar signs a new agreement with Onko to commercialize Yondelis® in Turkey

PharmaMar Group reported net profit of €113.8M at June 30th, 2020

PharmaMar signs a new agreement with ADIUM PHARMA S.A. to commercialize Yondelis® in Latin America

PharmaMar has filed lurbinectedin for Temporary Marketing Authorisation with the Swiss Agency for Therapeutic Products

PharmaMar announces that the NCCN® (National Comprehensive Cancer Network) has added Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology in the U.S.

Boryung Pharmaceutical, PharmaMar’s partner in South Korea, announces superior potent results for plitidepsin (Aplidin®) against SARS-CoV-2